On January 19, 2026, Honeybear Biosciences Co., Ltd. (hereinafter “Honeybear”) and PET Pharm Biotech, a leading domestic manufacturer and service provider of nuclear medicine, officially signed a strategic Memorandum of Understanding (MOU). Through this collaboration, the two parties will jointly advance local clinical trials and industry–academia–research collaborative development of Antibody Radionuclide Conjugates (ARC), marking a significant milestone for innovation in precision medicine and nuclear medicine in Taiwan.
This strategic partnership integrates Honeybear’s strong R&D foundation in developing next-generation ADC with PET Pharm Biotech’s industrial expertise in nuclear medicine manufacturing, supply, and radiopharmaceutical processing. Together, the partners aim to overcome the current bottleneck in ARC development, where radionuclide labeling often relies on overseas resources, and to establish a fully integrated Taiwan-based hub for ARC research, development, and clinical validation.
Honeybear Biosciences has focused on novel antibody and ADC site-specific conjugation technologies, as well as global new drug development. Leveraging its proprietary CoNectar® technology platform, the company continues to drive innovation in the ADC/ARC field. Following the authorization and collaboration agreement with Singapore’s Agency for Science, Technology and Research (A*STAR) in 2025, Honeybear Biosciences has accelerated ARC research and clinical translation efforts. Through this collaboration with PET Pharm Biotech, Honeybear Biosciences aims to complete the U.S. IND (Investigational New Drug) application for its HB001 program in 2026 and to progressively initiate ARC clinical trials in both Taiwan and the United States.
As one of Taiwan’s most representative radiopharmaceutical manufacturers, PET Pharm Biotech operates a PIC/S GMP-compliant sterile radiopharmaceutical manufacturing facility and possesses strong local nuclear medicine supply capabilities. Its expertise in nuclear medicine and radiopharmaceutical processing will serve as a critical pillar supporting both preclinical and clinical development of ARC therapies. The MOU not only strengthens the technological reciprocal between the two companies but is also expected to accelerate the localization and internationalization of Taiwan’s nuclear medicine drug development.
According to media reports, ARC therapies, combining the targeting specificity of antibodies with the diagnostic imaging or therapeutic benefits of radionuclides, are regarded as one of the key next-generation ADC modalities beyond traditional ADCs. They hold significant promises for improving precision and reducing side effects in cancer treatment. This collaboration symbolizes an important step toward integrated innovation across Taiwan’s biomedical value chain to realize the new drug development from bench to bedside.
Moving forward, Honeybear Biosciences and PET Pharm Biotech will implement concrete collaboration plans in accordance with the MOU, progressively strengthening their strategic alignment in ARC product development, clinical resource integration under the partnerships, and jointly shaping the future of Taiwan’s nuclear and precision medicine industries.
Please visit the related news link for more details：
This strategic partnership integrates Honeybear’s strong R&D foundation in developing next-generation ADC with PET Pharm Biotech’s industrial expertise in nuclear medicine manufacturing, supply, and radiopharmaceutical processing. Together, the partners aim to overcome the current bottleneck in ARC development, where radionuclide labeling often relies on overseas resources, and to establish a fully integrated Taiwan-based hub for ARC research, development, and clinical validation.
Honeybear Biosciences has focused on novel antibody and ADC site-specific conjugation technologies, as well as global new drug development. Leveraging its proprietary CoNectar® technology platform, the company continues to drive innovation in the ADC/ARC field. Following the authorization and collaboration agreement with Singapore’s Agency for Science, Technology and Research (A*STAR) in 2025, Honeybear Biosciences has accelerated ARC research and clinical translation efforts. Through this collaboration with PET Pharm Biotech, Honeybear Biosciences aims to complete the U.S. IND (Investigational New Drug) application for its HB001 program in 2026 and to progressively initiate ARC clinical trials in both Taiwan and the United States.
As one of Taiwan’s most representative radiopharmaceutical manufacturers, PET Pharm Biotech operates a PIC/S GMP-compliant sterile radiopharmaceutical manufacturing facility and possesses strong local nuclear medicine supply capabilities. Its expertise in nuclear medicine and radiopharmaceutical processing will serve as a critical pillar supporting both preclinical and clinical development of ARC therapies. The MOU not only strengthens the technological reciprocal between the two companies but is also expected to accelerate the localization and internationalization of Taiwan’s nuclear medicine drug development.
According to media reports, ARC therapies, combining the targeting specificity of antibodies with the diagnostic imaging or therapeutic benefits of radionuclides, are regarded as one of the key next-generation ADC modalities beyond traditional ADCs. They hold significant promises for improving precision and reducing side effects in cancer treatment. This collaboration symbolizes an important step toward integrated innovation across Taiwan’s biomedical value chain to realize the new drug development from bench to bedside.
Moving forward, Honeybear Biosciences and PET Pharm Biotech will implement concrete collaboration plans in accordance with the MOU, progressively strengthening their strategic alignment in ARC product development, clinical resource integration under the partnerships, and jointly shaping the future of Taiwan’s nuclear and precision medicine industries.
Please visit the related news link for more details：
- 聯合新聞網 吉晟生、嘉正簽訂 MOU（聯合報）
- 經濟日報／聯合新聞網（證券/財經版）吉晟生、嘉正簽訂 MOU（經濟日報）
- 聯合新聞網 吉晟生與嘉正策略聯盟首創抗體放射複合體（聯合報）
- 自由財經 吉晟攜手嘉正生技 落實台灣首創ARC在地臨床試驗（自由財經）
- 鉅亨網 吉晟與嘉正簽訂合作備忘錄 加速台灣抗體放射複合體在地臨床試驗 | 鉅亨網 - 台股新聞
- 優分析UAnalyze吉晟與嘉正簽訂合作備忘錄 加速台灣抗體放射複合體在地臨床試驗（優分析）
- Yahoo! 財經／MoneyDJ 嘉正、吉晟生策盟 加速ARC臨床試驗在地化（Yahoo!財經）
- PChome Online 新聞 吉晟生技攜手嘉正｜PChome Online 新聞
- 4gTV／四季線上吉晟攜手嘉正生技 評估核醫與放射藥合作｜4gTV
Sarina Lin, Vice Chairwoman of Honeybear Biosciences (middle left) and
Edward Wang, Chairman of Honeybear Biosciences (middle right)
lead the team to attend the signing ceremony of MOU between Honeybear Biosciences and PET Pharm Biotech.
Edward Wang, Chairman of Honeybear Biosciences (middle right)
lead the team to attend the signing ceremony of MOU between Honeybear Biosciences and PET Pharm Biotech.
(From left to right)
Sarina Lin, Vice Chairwoman of Honeybear Biosciences,
Edward Wang, Chairman of Honeybear Biosciences,
Sarina Lin, Vice Chairwoman of Honeybear Biosciences,
Edward Wang, Chairman of Honeybear Biosciences,
John Yang, Chairman of PET Pharm Biotech,
Terry Lin, General Manager of PET Pharm Biotech.
Terry Lin, General Manager of PET Pharm Biotech.
